cells. This comes as no surprise, since the ethical problems related to bone marrow transplantation (BMT) in pediatrics, first applied successfully almost 30 years ago, 1,2 have not The two most widely used sources of hematopoietic stem cells for allogeneic transplants in pediatric practice are been entirely settled. It must also be emphasized that, in children, the use of peripheral blood stem cells mobilized bone marrow (BM) and cord blood (CB). While bone marrow transplantation (BMT) is reaching its 30th year through hematopoietic growth factors is not accepted routinely, as the possibility of long-term adverse effects from of application, human umbilical cord blood transplantation (HUCBT) is approaching its 10th. Although these this practice has not yet been ruled out and it is approved occasionally for specific indications, such as second transprocedures have basically the same purpose, a number of biological differences distinguish them. In particular, plant after a first rejection of donor marrow. Although well-grounded consensus on application 3-7 prethe intrinsically limited quantity of CB stem cells and their immunological naiveté confer peculiar charactervails for marrow transplantation over what are now merely occasional reservations, 8 it seems relevant to compare the istics to these hematopoietic progenitors. From a bioethical point of view, the problems which have repeatprerogatives of the two practices (BMT and HUCBT) and their bioethical profile in pediatrics, revisiting them as edly been raised when the BM donor is a child are wellknown. Different but no less important ethical problems plainly as possible in the light of the four now traditional and basic guiding principles of bioethics, namely autonomy, are raised when one considers HUCBT; in this regard the most important issues are the easier propensity of nonmaleficence, beneficence, and justice. A concise review, dedicated separately to each programming a CB donor in comparison with a BM donor (clearly due to the shorter time interval needed procedure, is basically inspired by a comparison of the two, ultimately allowing an approach to their respective to collect the hematopoietic progenitors); the in utero HLA-typing; the implication of employing 'blood prerogatives. belonging to a neonate' for a third party; the need to perform a number of investigations both on the CB of the donor and on the mother and the implications that Bone marrow transplantation as a traditional approach for transplanting hematopoietic stem cells the discovery of disease may have for them, but also the need to establish banks for storing CB, with the accompanying administration and management probAs in all choices and decisions that concern the child, with its intrinsic lack of autonomy or with its limitations (also lems. All these different aspects of UCBT will be discussed in the light of the four fundamental and traapplicable to the adolescent), in BMT too any decision can only be validated by the informed consent of the parents ditional principles of bioethics, namely autonomy, nonmaleficence, beneficence and justice.
23 centuries old, as well as the need to rephrase it 10 as 'do Transplant of cord blood progenitor cells as little harm as possible' or 'do no harm unless that harm This transplant, used clinically only in recent times (the is necessarily associated with a compensating benefit'. first use was in 1988), 19, 20 has now been put to the test by If, in the risk/benefit (or cost/benefit or cost-detriment/ approximately 300 procedures. It covers areas which used benefit) balance, the minimal risks affecting the donor are to be within the scope of BMT, but its bioethical profile is compensated, according to a reasonable prediction, by sigsignificantly different. nificant potential benefits for the recipient-patient, as occurs
The placenta and the umbilical cord are temporary, shortfor allogeneic BMT from an HLA-compatible sibling or lived structures whose physiological function is important unrelated volunteer, compliance with nonmaleficence though limited in time. Apart from use for research (which becomes immediately evident.
also entails careful ethical thought), 21 the placenta has not The cost/benefit evaluation is also based on this issue.
been used in practice except in the last 8 years; indeed, it The fact that compliance with beneficence is achieved used to be routinely disposed of at the end of the delivery. almost as a consequence seems indeed a corollary, at least Their temporary and disposable nature have placed the as regards the recipient-patient; but some thought has been placenta and the cord among 'discarded tissues': a classirightfully given to the role of the donor, since the existential fication which is certainly significant also from an ethical reward related to 'having donated one's own in order to viewpoint concerning the value of using these tissues, 22, 23 save someone' 11-13 abundantly repays the donor of any including the possibility of not having to obtain the 'conrisks and costs caused by possible suffering.
sent' of the donor (of the pregnant woman and possibly of On the other hand, one cannot rule out a possible sense her partner).
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of guilt as a consequence of a refusal to donate. 14,15 A very However, this simplification has been promptly negyoung child donor may experience gratification or, vice lected. 24 Parents may make decisions as guardians for their versa, a sense of guilt later on and include them in his or child and their actions should be measured in terms of the her life experience.
benefit of their decision to the child. 25 Indeed, the consent Obviously, even such a globally favorable assessment of of the parents (especially of the mother) to use cord blood BMT does not implicitly comply with the principle of jus-(CB) is considered standard practice. In particular, infortice, since this principle involves at least evaluations conmed consent to donate should appropriately be obtained cerning the context; for example, the financial resources from the woman before she is emotionally involved in available, which must be taken into account, especially for delivery (ie during the last 3 months of pregnancy). populations having a modest per capita income level. Other However, one must still ask oneself, with regard to these context-related evaluations, which might induce problems considerations, who would ever have claimed 'ownership' regarding justice, could also arise within the family or from of the placenta and the cord before today? Yet today the considerations related to particular circumstances. Hence, placenta has acquired immense dignity, since the hematofor example, the intense debate in Europe and in the United poietic stem cells that its blood contains have been recogStates on the problem of transplants from a sibling connized as a precious 'life-saving' capital. Therefore, the preceived with the hope of producing a compatible donor for viously mentioned question, which was irrelevant a previous child requiring BMT: 'programming a bone marhistorically, now takes on an increasingly important sigrow donor'; 16 'conceiving a child to save a child'; 17 'the nificance. child conceived to give life'.
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'Ownership' of the placenta, which is well-known to Our experience with a child with chronic myelogenous 'belong' to the neonate, becomes important because of the leukemia is now over 10 years old 4, 16 and has been extradestination of its blood, which might be needed by another ordinarily rewarding for the family who experienced it. Of 'recipient' (for an allotransplant) within the family or outcourse, any decision to conceive a child for the sole purpose side it, or in theory by the very child who had been nourof making it become a bone marrow donor (or a cord blood ished by it during prenatal life, in other words by the donor) entails belittling the value of the individual to be 'donor', with the prospect of an autotransplant. Manageborn, viewed as a human being having a dignity of its own. ment of cord blood therefore assumes a very specific meanHowever, it cannot be ignored that it is extremely difficult ing: avoiding the elimination of a 'life-saving' capital can to separate the reasons that lead to the conception of a child be important, to the point of raising commercial interests, solely for the joy of procreating from those linked to the with the risk of severe ethical failures. possibility of saving a living, sick child.
Whoever has the right to decide over the placenta (it In summary, regarding BMT in pediatrics, one can conseems obvious to consider the parents, also because they clude that it has been confirmed as an ethical practice, are 'naturally' responsible for the neonate and for the because its benefits abundantly prevail over its costs and decisions to be made in his best interests) 21 must be able risks, because it fully complies with primum non nocere to do so in autonomy and therefore must be informed not as rephrased, 10 because it is an act of rewarding altruism only of the intrinsic and natural transience of the func-(sometimes perhaps an involuntary one), and because it is tionality of the placenta, but also of any expectation and in any case a practice of solidarity. Ultimately, it is an intention to use it (or its blood) and of any implication, example of one of the advanced biotechnologies which including the need for numerous diagnostic tests on the have progressively been proposed with the very purpose of blood of the mother and on the cord blood before using it increasing the possibilities of life or of improving the (a complex issue requiring consideration, also according to the principle of justice, to which we will return). quality of life. used to eliminate the placenta; now it might be interested Lower incidence of psychological problems related to the figure of in managing or helping with its management, 29 especially the child-donor and to possible transplant failure since the placenta, far from continuing to be classified among discarded tissues, can be considered a 'bank' organ (or tissue), with all the implications entailed by this program, which unfortunately also includes the interest of This peculiar transplant, as in any case all others, must commercial companies, with the prospect of profit and produce beneficence; that is to say, it must provide advantherefore with a risk for ethics and for the pedagogical tages (possibly better ones than those offered by any alterimage. 22 native method). The fact that broadly speaking this proConsider also the preservation of the blood itself, on the cedure complies with nonmaleficence is already obvious, one hand (with its associated costs) and the different and since at the time of collection no tissue truly useful to the possibly contrasting purpose for which it is stored donor is removed and no pain at all is caused.
(allotransplant or hypothetically, autotransplant), on the Whether a somewhat early clamping of the umbilical other hand. Obviously, since the CB cells to be transplanted cord (5-10 s 26 or 34-45 s 27 'after birth'), while being are intrinsically available in limited quantity, the possibility responsible for a mild anemia, 21 can negatively affect the of an allotransplant would in fact irreparably damage the neonate in any way has been the subject of discussion, 28 but donor, preventing autotransplantation. Indeed, Gluckman et has also been conclusively disproved. 29 Besides, unwanted al 30 quite correctly considered, among the clauses which effects in the recipient, for example, graft-versus-host disshould be accepted for consent, mutual anonymity of donor ease, are if anything, significantly less worrisome than and recipient and non-commitment to autotransplantation. those which can occur after BMT (see also Tables 1 and 2 Moreover, to allow the decision to mature and become for advantages and disadvantages associated with cord well-thought consent, the woman and the father of her child blood transplantation). Accordingly, the ethical assessment must immediately be made aware that it is necessary to of this dyad (nonmaleficence-beneficence) is particularly perform all the tests required to recognize suitable and favorable, besides being easy, for the use of CB progenitor usable cord blood, with no risk of transmitting to the recipient any disease carried by the cells which would be Information and clinical checks as to the health of the mum number of cells to be infused for a successful CB transplantation has been claimed to be 1 × 10 7 nucleated infant and the mother must in any case be gathered according to a 'look-forward' program. 31 Moreover, it will be cells per kg of recipient body weight. 20 However, recent data suggest that the higher the infused cellular load, the necessary to consider the possibility of performing future tests on the placental blood, if new tests are proposed in higher the likelihood of success of the transplant. Specifically, the dose of 3.7 × 10 7 nucleated cells per kg of recipithe future to check for diseases which cannot be detected at present: we face the possibility of 'informed consent for ent body weight seems to be the critical minimum allowable value. 42 These considerations explain why processes look-back testing'. Should this policy fail to be implemented, or should the possibility of donor control be for the in vitro expansion of cord blood progenitor cells by using cytokines continue to be extremely interesting for lost, any recipient ought to be warned of this fact. 31 However, when one considers the practical application routine application of HUCBT in adults.
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In any case, there is a great 'quantitative' difference in of these problems, questions arise immediately. In particular, what kind of behavior should be adopted by the the cell availability provided by the two different tissues: bone marrow is the only one of the two which regenerates medical operator who works with a woman (or with the parents of a child) if a hereditary disease for which there continuously, and should an allotransplant donor require some for an autotransplant, he would have it available, is no therapy is detected in the infant? 24 One might recall, in this regard, that it has been stated that 'The purpose of whereas of course placental blood is only available in the amount collected and stored (only once). In other words, ethics in medicine is to reduce the likelihood of moral tragedy by subjecting moral dilemmas to systematic, rational if the cell repertory of a cord blood were assigned to an allotransplant, the donor would not have it available if he analysis'. 32 Moreover, it must be noted that a 1994 Institute of Medicine review recommends that minors not be tested needed it for an autologous transplant. An important problem of justice, indeed a fundamental one, has developed for abnormal genes unless there is an effective curative or preventive treatment that must be instituted early in life. 33 out of this lack of availability: if the parents decide 'in the best interests' of their newborn child, the only goal of In presenting the above considerations, we have mainly taken into account the model of use of the CB cells of the preservation (banking) of placental blood is to cater for the possible need for an autotransplant.
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neonate with regard to allotransplant. However, in the same way in which BMT can be performed extemporaneously However, it is evident that from this viewpoint, that is to say, if one intended to ensure that every possible blood between HLA-compatible related individuals, or can be programmed depending on the finding of an unrelated donor had the right possibly to use the donated blood for himself, there would be no way to provide cord blood units donor in a registry, so can multiple possibilities be provided for HUCBT. 34 Indeed, there may be an extemporaneous for allotransplants. This is an attitude which obviously will not prevail. While it is true that it would be an authentic use, that is to say, for a patient for whom a compatible sibling is born with good timing; or, vice versa, there may 'insurance policy', an enormous amount of material, with an equally enormous expense, would remain unused, with be an application from an unrelated donor after finding compatible CB, stored in a bank perhaps for a long time.
a clearly unacceptable cost/benefit balance. Only approximately one child in 50 000 in fact requires, every year, cytoIn the first case, it is important to stress the inappropriateness of performing HLA typing in utero. Because of the static therapy in high doses with subsequent support by means of hematopoietic progenitor cells. Besides, the very abortion risks linked to the procedure, it entails the risk of causing the death of a healthy human being and would in nature of the technique, conceived originally for allotransplants, would be transformed profoundly and it would punany case be deeply despicable if it were used to dispose of a conceived child found to be HLA-incompatible with the ish all of 'donation ethics' at its very core. Those outlined above are certainly not the only problems sick patient. HLA typing in utero should be performed, in our opinion, only when other, far more important reasons that form the bioethical burden of justice for CB. The different political and economic programs for using the finan-(for example, advanced age of the mother, with consequent higher risk of chromosome 21 trisomy for the fetus) suggest cial resources of individual nations and societies, which allow or prevent the establishment of cord banks, with all the execution of prenatal diagnosis procedures.
The second possibility, that is to say, the possibility of the corollary requirements and tasks, obviously come before any personal prospects with regard to the basic using the placental blood for transplants between unrelated individuals, is furthermore the commonest and is necessarchoices (whether to allow or not allow collection and banking) and are still a highly problematic aspect of the ily associated with efficient bank organizations, which are now being fully planned and created in the USA, Europe, project. The question of private (for-profit vs non-profit) banking and Australia. 26, 30, [35] [36] [37] It is true that it has been recently demonstrated that even of CB cells has been thoroughly analyzed. 22 In any case, the involvement of lucrative aspects in the technology of adults can be cured by HUCBT despite the infusion of a relatively small dose of nucleated cells. This has been cord cell transplantation is not acceptable. The need to create banks for collection must not allow for-profit projects; ascribed to the particular hematopoietic reconstitution capabilities of CB hematopoietic stem cells with respect to bone in particular, CB cells like any part of the human body should not be commercialized. 33, 43 To be very cautious in marrow cells. [38] [39] [40] Previous estimates indicated that usual practice in allogeneic BMT is to infuse 1-3 × 10 8 nucleated an approach that is particularly sensitive to these economic 
